The US is the bigger Diabetic Retinopathy Drugs market: $4.5 Bn against $868 Mn in 2023, about 5.2 times as large.
China grows faster: 7.5% a year, against 4%. The gap still grows from $3.7 Bn to $4.9 Bn by 2033.
Clinical research: 77 active trials in the US, 34 in China.
| Measure |  US |  China |
|---|---|---|
| Market size, 2023 | $4.5 Bn | $868 Mn |
| Market size, 2033 projected | $6.7 Bn | $1.8 Bn |
| Growth a year (CAGR) | 4% | 7.5% |
| Money added, 2023–2033 | $2.2 Bn | $921 Mn |
| Share of the world market | 42% | 8% |
| Size rank of 24 countries | #1 | #2 |
| Market per person, 2023 | $13 | $0.62 |
| Active clinical trials | 77 | 34 |
| Diabetes (adults) % of adults (WHO) | 12.5 2022 | 11.2 2022 |
| Full report | US report | China report |
Year by year, 2023 to 2033
US China · values between 2023 and 2033 are projected from the 2023 size and the CAGR.
Quick answers
Which is bigger in Diabetic Retinopathy Drugs, US or China?
The US is the bigger Diabetic Retinopathy Drugs market: $4.5 Bn against $868 Mn in 2023, about 5.2 times as large.
Which grows faster in Diabetic Retinopathy Drugs, US or China?
China grows faster: 7.5% a year, against 4%. The gap still grows from $3.7 Bn to $4.9 Bn by 2033.
More Diabetic Retinopathy Drugs comparisons
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide. Health figures: WHO. Population: World Bank.